aadlogo.jpg
How to Check Your Nails for Melanoma; American Academy of Dermatology
May 11, 2021 14:00 ET | American Academy of Dermatology
ROSEMONT, Ill., May 11, 2021 (GLOBE NEWSWIRE) -- When checking the body for signs of skin cancer, many people may only think to check their skin. However, board-certified dermatologists from the...
aadlogo.jpg
New American Academy of Dermatology Survey Finds One-Third of Americans Fail Basic Quiz on Skin Cancer and Sun Exposure
April 27, 2021 14:52 ET | American Academy of Dermatology
ROSEMONT, Ill., April 27, 2021 (GLOBE NEWSWIRE) -- In a recent survey of 1,000 U.S. adults, the American Academy of Dermatology found that one-third of Americans lack a basic understanding of skin...
22157.jpg
Global Immuno-Oncology Market Report 2021-2026: Merck's Keytruda (Pembrolizumab) Leads the Market
March 29, 2021 06:53 ET | Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Market Analysis, Trends, Opportunities and Unmet Needs - Thematic Research" report has been added to ResearchAndMarkets.com's...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
March 18, 2021 16:15 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of...
22157.jpg
$135 Billion Immuno-Oncology Markets, 2024
January 07, 2021 08:13 ET | Research and Markets
Dublin, Jan. 07, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Market, by Type (mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)), by Application (Lung,...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
December 15, 2020 08:05 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
September 15, 2020 07:18 ET | Idera Pharmaceuticals, Inc.
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
aad.jpg
How To Prevent And Treat Common Summer Rashes; American Academy of Dermatology
August 11, 2020 14:30 ET | American Academy of Dermatology
ROSEMONT, Ill., Aug. 11, 2020 (GLOBE NEWSWIRE) -- As the coronavirus continues to spread throughout the country, many people may find themselves spending more time outdoors for a much-needed change...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech gibt Kollaboration mit Regeneron zur Entwicklung einer Melanom-Kombinationstherapie aus FixVac und Libtayo® (Cemiplimab) bekannt
July 31, 2020 02:00 ET | BioNTech SE
BioNTech und Regeneron planen die gemeinsame Durchführung einer randomisierten Phase-2-Studie mit einer Kombination aus FixVac BNT111 und Libtayo für die Behandlung von maligem Melanom (schwarzer...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma
July 31, 2020 02:00 ET | BioNTech SE
BioNTech and Regeneron plan to jointly conduct a randomized Phase 2 study combining BNT111 FixVac and Libtayo for the treatment of melanoma that has progressed after prior PD-1 blockadeCombines two...